Don’t miss ASCO (American Society of Clinical Oncology) 2026 and the RET specific presentations.
The 2026 ASCO Annual Meeting 2026, taking place May 29–June 2 in Chicago, will feature an exciting lineup of presentations highlighting major advances in RET-positive cancers. From practice-changing phase 3 trials in early stage RET NSCLC to promising next-generation RET inhibitors and new data in thyroid and other solid tumors, this year’s meeting reflects the rapid momentum in RET cancer research.
Plenary Session: Special Sessions
May 31st 1:00 – 4:00 PM CDT
Hall B1 | Live Stream 2:13 – 2:25 PM CDT
Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.
Jonathan W. Goldman, MD
Abstract LBA3
Oral Abstract SessionLung Cancer—Non-Small Cell MetastaticLung Cancer—Non-Small Cell Metastatic
May 29th 1:00 – 4:00 PM CDT
Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase II study in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC).
2:36 – 2:48 PM CDT
Qing Zhou, MD, PhD
Abstract 8505
Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Poster Session: Head and Neck Cancer
May 30th 1:30 – 4:30 PM CDT
Poster Session: Lung Cancer—Non-Small Cell Metastatic
RET fusion–positive lung adenocarcinoma: Partner-specific clinicopathological characteristics, co-mutation profiles, and implications for targeted and immunotherapy.
Zihan Sun, PhD
Abstract 8615
Poster 405
Clinical efficacy and tolerability of the selective RET inhibitor soxataltinib (SY-5007) in advanced RET fusion–positive non–small cell lung cancer (NSCLC): Primary findings from a confirmatory phase III trial.
